Review of Metformin Use for Type 2 Diabetes Prevention

Tannaz Moin, Julie A. Schmittdiel, James H. Flory, Jessica Yeh, Andrew J. Karter, Lydia E. Kruge, Dean Schillinger, Carol M. Mangione, William H. Herman, Elizabeth A. Walker

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Context: Prediabetes is prevalent and significantly increases lifetime risk of progression to type 2 diabetes. This review summarizes the evidence surrounding metformin use for type 2 diabetes prevention. Evidence acquisition: Articles published between 1998 and 2017 examining metformin use for the primary indication of diabetes prevention available on MEDLINE. Evidence synthesis: Forty articles met inclusion criteria and were summarized into four general categories: (1) RCTs of metformin use for diabetes prevention (n=7 and n=2 follow-up analyses); (2) observational analyses examining metformin use in heterogeneous subgroups of patients with prediabetes (n=9 from the Diabetes Prevention Program, n=1 from the biguanides and the prevention of the risk of obesity [BIGPRO] trial); (3) observational analyses examining cost effectiveness of metformin use for diabetes prevention (n=11 from the Diabetes Prevention Program, n=1 from the Indian Diabetes Prevention Program); and (4) real-world assessments of metformin eligibility or use for diabetes prevention (n=9). Metformin was associated with reduced relative risk of incident diabetes, with the strongest evidence for use in those at highest risk (i.e., aged <60 years, BMI ≥35, and women with histories of gestational diabetes). Metformin was also deemed cost effective in 11 economic analyses. Recent studies highlighted low rates of metformin use for diabetes prevention in real-world settings. Conclusions: Two decades of evidence support metformin use for diabetes prevention among higher-risk patients. However, metformin is not widely used in real-world practice, and enhancing the translation of this evidence to real-world practice has important implications for patients, providers, and payers.

Original languageEnglish (US)
JournalAmerican Journal of Preventive Medicine
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Metformin
Type 2 Diabetes Mellitus
Prediabetic State
Biguanides
Gestational Diabetes
MEDLINE
Cost-Benefit Analysis
Obesity
Economics
Costs and Cost Analysis

ASJC Scopus subject areas

  • Epidemiology
  • Public Health, Environmental and Occupational Health

Cite this

Moin, T., Schmittdiel, J. A., Flory, J. H., Yeh, J., Karter, A. J., Kruge, L. E., ... Walker, E. A. (Accepted/In press). Review of Metformin Use for Type 2 Diabetes Prevention. American Journal of Preventive Medicine. https://doi.org/10.1016/j.amepre.2018.04.038

Review of Metformin Use for Type 2 Diabetes Prevention. / Moin, Tannaz; Schmittdiel, Julie A.; Flory, James H.; Yeh, Jessica; Karter, Andrew J.; Kruge, Lydia E.; Schillinger, Dean; Mangione, Carol M.; Herman, William H.; Walker, Elizabeth A.

In: American Journal of Preventive Medicine, 01.01.2018.

Research output: Contribution to journalArticle

Moin, T, Schmittdiel, JA, Flory, JH, Yeh, J, Karter, AJ, Kruge, LE, Schillinger, D, Mangione, CM, Herman, WH & Walker, EA 2018, 'Review of Metformin Use for Type 2 Diabetes Prevention', American Journal of Preventive Medicine. https://doi.org/10.1016/j.amepre.2018.04.038
Moin, Tannaz ; Schmittdiel, Julie A. ; Flory, James H. ; Yeh, Jessica ; Karter, Andrew J. ; Kruge, Lydia E. ; Schillinger, Dean ; Mangione, Carol M. ; Herman, William H. ; Walker, Elizabeth A. / Review of Metformin Use for Type 2 Diabetes Prevention. In: American Journal of Preventive Medicine. 2018.
@article{5738db15ee2d4ab68d18aa00b80ae6d2,
title = "Review of Metformin Use for Type 2 Diabetes Prevention",
abstract = "Context: Prediabetes is prevalent and significantly increases lifetime risk of progression to type 2 diabetes. This review summarizes the evidence surrounding metformin use for type 2 diabetes prevention. Evidence acquisition: Articles published between 1998 and 2017 examining metformin use for the primary indication of diabetes prevention available on MEDLINE. Evidence synthesis: Forty articles met inclusion criteria and were summarized into four general categories: (1) RCTs of metformin use for diabetes prevention (n=7 and n=2 follow-up analyses); (2) observational analyses examining metformin use in heterogeneous subgroups of patients with prediabetes (n=9 from the Diabetes Prevention Program, n=1 from the biguanides and the prevention of the risk of obesity [BIGPRO] trial); (3) observational analyses examining cost effectiveness of metformin use for diabetes prevention (n=11 from the Diabetes Prevention Program, n=1 from the Indian Diabetes Prevention Program); and (4) real-world assessments of metformin eligibility or use for diabetes prevention (n=9). Metformin was associated with reduced relative risk of incident diabetes, with the strongest evidence for use in those at highest risk (i.e., aged <60 years, BMI ≥35, and women with histories of gestational diabetes). Metformin was also deemed cost effective in 11 economic analyses. Recent studies highlighted low rates of metformin use for diabetes prevention in real-world settings. Conclusions: Two decades of evidence support metformin use for diabetes prevention among higher-risk patients. However, metformin is not widely used in real-world practice, and enhancing the translation of this evidence to real-world practice has important implications for patients, providers, and payers.",
author = "Tannaz Moin and Schmittdiel, {Julie A.} and Flory, {James H.} and Jessica Yeh and Karter, {Andrew J.} and Kruge, {Lydia E.} and Dean Schillinger and Mangione, {Carol M.} and Herman, {William H.} and Walker, {Elizabeth A.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.amepre.2018.04.038",
language = "English (US)",
journal = "American Journal of Preventive Medicine",
issn = "0749-3797",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Review of Metformin Use for Type 2 Diabetes Prevention

AU - Moin, Tannaz

AU - Schmittdiel, Julie A.

AU - Flory, James H.

AU - Yeh, Jessica

AU - Karter, Andrew J.

AU - Kruge, Lydia E.

AU - Schillinger, Dean

AU - Mangione, Carol M.

AU - Herman, William H.

AU - Walker, Elizabeth A.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Context: Prediabetes is prevalent and significantly increases lifetime risk of progression to type 2 diabetes. This review summarizes the evidence surrounding metformin use for type 2 diabetes prevention. Evidence acquisition: Articles published between 1998 and 2017 examining metformin use for the primary indication of diabetes prevention available on MEDLINE. Evidence synthesis: Forty articles met inclusion criteria and were summarized into four general categories: (1) RCTs of metformin use for diabetes prevention (n=7 and n=2 follow-up analyses); (2) observational analyses examining metformin use in heterogeneous subgroups of patients with prediabetes (n=9 from the Diabetes Prevention Program, n=1 from the biguanides and the prevention of the risk of obesity [BIGPRO] trial); (3) observational analyses examining cost effectiveness of metformin use for diabetes prevention (n=11 from the Diabetes Prevention Program, n=1 from the Indian Diabetes Prevention Program); and (4) real-world assessments of metformin eligibility or use for diabetes prevention (n=9). Metformin was associated with reduced relative risk of incident diabetes, with the strongest evidence for use in those at highest risk (i.e., aged <60 years, BMI ≥35, and women with histories of gestational diabetes). Metformin was also deemed cost effective in 11 economic analyses. Recent studies highlighted low rates of metformin use for diabetes prevention in real-world settings. Conclusions: Two decades of evidence support metformin use for diabetes prevention among higher-risk patients. However, metformin is not widely used in real-world practice, and enhancing the translation of this evidence to real-world practice has important implications for patients, providers, and payers.

AB - Context: Prediabetes is prevalent and significantly increases lifetime risk of progression to type 2 diabetes. This review summarizes the evidence surrounding metformin use for type 2 diabetes prevention. Evidence acquisition: Articles published between 1998 and 2017 examining metformin use for the primary indication of diabetes prevention available on MEDLINE. Evidence synthesis: Forty articles met inclusion criteria and were summarized into four general categories: (1) RCTs of metformin use for diabetes prevention (n=7 and n=2 follow-up analyses); (2) observational analyses examining metformin use in heterogeneous subgroups of patients with prediabetes (n=9 from the Diabetes Prevention Program, n=1 from the biguanides and the prevention of the risk of obesity [BIGPRO] trial); (3) observational analyses examining cost effectiveness of metformin use for diabetes prevention (n=11 from the Diabetes Prevention Program, n=1 from the Indian Diabetes Prevention Program); and (4) real-world assessments of metformin eligibility or use for diabetes prevention (n=9). Metformin was associated with reduced relative risk of incident diabetes, with the strongest evidence for use in those at highest risk (i.e., aged <60 years, BMI ≥35, and women with histories of gestational diabetes). Metformin was also deemed cost effective in 11 economic analyses. Recent studies highlighted low rates of metformin use for diabetes prevention in real-world settings. Conclusions: Two decades of evidence support metformin use for diabetes prevention among higher-risk patients. However, metformin is not widely used in real-world practice, and enhancing the translation of this evidence to real-world practice has important implications for patients, providers, and payers.

UR - http://www.scopus.com/inward/record.url?scp=85051649148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051649148&partnerID=8YFLogxK

U2 - 10.1016/j.amepre.2018.04.038

DO - 10.1016/j.amepre.2018.04.038

M3 - Article

JO - American Journal of Preventive Medicine

JF - American Journal of Preventive Medicine

SN - 0749-3797

ER -